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Background: Procalcitonin (PCT) is a reliable biomarker of sepsis and infection. The level of PCT associated with
sepsis and infection in patients with traumatic brain injury is currently unknown. The purpose of this study was to
investigate the value of PCT and C-reactive protein (CRP) as diagnostic markers of sepsis and to evaluate the prognostic
value of these markers related to the severity of injury, sepsis and mortality.
Methods: 105 adult patients with neurotrauma were enrolled in this study from June 2011 to February 2013. PCT and
CRP were measured at admission and 2, 3, 5 and 7 days after admission. The sepsis criteria established by American
College of Chest Physicians /Society of Critical Care Medicine Consensus Conference were used to identify patients.
Injury Severity Score (ISS) and Glasgow Coma Score (GCS) were used to assess the severity of the injury. All these
patients were monitored for 28 days.
Results: At admission, the median level of PCT was consistent with the severity of brain injury as follows: mild 0.08 ng/ml
(0.05 - 0.13), moderate 0.25 ng/ml (0.11 - 0.55) and severe 0.31 ng/ml (0.17 - 0.79), but the range of CRP
levels varied greatly within the given severity of brain injury. Seventy-one (67.6%) patients developed sepsis.
The initial levels of PCT at admission were statistically higher in patients with sepsis, compared with patients with
systemic inflammatory response syndrome (SIRS), but there were no differences in the initial concentration of CRP
between sepsis and SIRS. After adjusting for these parameters, multivariate logistic regression analysis revealed that
PCT was an independent risk factor for septic complications (p < 0.05). The areas under the ROCs at admission for the
prediction of mortality were 0.76 (p < 0.05) and 0.733 for PCT and CRP, respectively.
Conclusions: Increased levels of PCT during the course of the ICU stay could be an important indicator for the early
diagnosis of sepsis after neurotrauma. In addition, high serum levels of PCT in patients with neurotrauma at admission
indicate an increased risk of septic complications, and the daily measurement of PCT assists in guiding antibiotic
therapy in neurotrauma patients.
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Traumatic brain injury (TBI) accounts for a large proportion
of injury-related deaths and disabilities in developed
countries [1]. Patients with TBI have an increased risk
of consequent infection and sepsis, which requires
prompt diagnosis and treatment with appropriate
antimicrobial agents to reduce associated morbidity and
mortality [2-4]. Severe neurotrauma is a great potential
cause of systemic inflammatory response syndrome (SIRS)* Correspondence: caotongwa@sohu.com
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reproduction in any medium, provided the or[5], and the currently available markers including
fever, C-reactive protein (CRP), IL-6 and total leukocyte
count lack sensitivity and specificity thereby making it
difficult to distinguish SIRS from infectious diseases
[6]. Reducing the risk of infection and subsequent sepsis
through adherence to infection control measures is essential
to lower in-hospital deaths among patients with TBI.
In the last decade, several papers have been published
that report procalcitonin (PCT) as a novel biomarker that
is recommended for the assessment of bacterial infection
[7-11]. PCT is composed of 116 amino acids and is
physiologically synthesised by thyroid C cells, but in the
case of sepsis, there is an extrathyroidal origin of PCTtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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negligible, but they become detectable at the onset of
infection. PCT levels are closely related to the severity
and evolution of infection, and they are thought to be
associated with poor prognosis in patients with septicaemia
[12,13]. PCT has been used to evaluate the evolution of
infections and sepsis in patients with trauma and surgical
conditions [5,14,15]. The changes of PCT level in response
to therapeutic treatment have also been reported, which
suggests prognostic significance in a variety of clinical
settings [16,17]. The persistent increase of PCT level is
associated with an increased length of ICU stay and
mortality [18]. PCT-guided strategies have significantly
reduced the use of antibiotics [19]. Among the proposed
biomarkers of sepsis, PCT appears to be the most promis-
ing in terms of its diagnostic and prognostic benefits.
Recently, a newly developed PCT assay with significantly
higher discriminatory power has been put into practice
[20]. There is a lack of substantial data regarding the use
of PCT in the treatment of traumatic brain injury [5,21].
The aim of this study was to investigate the levels of
PCT and CRP that are used as diagnostic markers of
sepsis in patients with traumatic brain injury at the time
of hospital admission, and to evaluate the prognostic




After approval by the Ethics Committee of Huashan
Hospital, Fudan University, Shanghai, China (approval
number: 2011–281), informed consent was obtained
from each patient or their representatives. A total of 105
patients with isolated traumatic brain injury who were
admitted to the ICU of our tertiary university teaching
hospital from June 2011 to February 2013 were enrolled
in this prospective observational study. Patients were
included if they fulfilled the following criteria: age over
18 years old and admission within 24 hours of injury.
Patients with pre-existing febrile illness, suffering from
burns, an Abbreviated Injury Scale (AIS) for all other
body regions injury ≥ 3, patients under immune suppressive
therapy, patients already on antibiotics for ≥3 days before
admission, and patients who did not survive for 48 hours
after admission were excluded from the study.
Clinical data collection
All patients in the ICU were monitored by ECG and arter-
ial pressure monitoring as a part of routine clinic practice.
The clinical care of the patients was guided by the criteria
established by the Brain Trauma Foundation and the
American Association of Neurological Surgeons [22-24].
Endotracheal intubation was carried out, and mechanical
ventilation was initiated as clinically required. GlasgowComa Score (GCS) and Injury Severity Score (ISS) were
used to define the injury severity [25,26]. GCS and ISS
were calculated within the first 24 hours after admission
and were repeated every day thereafter. The levels of PCT
and CRP were measured on days 1 (admission day),
2, 3, 5 and 7. All data including clinical signs, laboratory
observations, microbiological pathogens, medicine options,
complications, 28-day survival rate and duration treatment
and length of stay in ICU as well as the data necessary to
evaluate the ISS were documented.
Definitions
The main complication was systemic inflammation, and
the various stages of sepsis were defined according to
the criteria established by the American College of Chest
Physicians/the Society of Critical Care Medicine [6]. We
evaluated the onset of sepsis during the first observation
week. Patients were allocated to four groups post hoc:
(1) NoSIRS (neither SIRS nor sepsis) (2) SIRS (3) sepsis
and (4) severe sepsis group (including severe sepsis and
septic shock).The stratification of trauma severity in terms
of the GCS score was generally recognised and accepted
by professionals [25]. Then, patients were allocated to
three groups post hoc: (1) GCS13-15 group (2) GCS9-12
group and (3) GCS3-8 group. The patients who survived
longer than 28 days were considered as survivors.
Measurement of plasma PCT and CRP
According to the manufacturer’s instructions, PCT
level was measured by an electrochemiluminescence
immunoassay (ECLIA) B.R.A.H.M.S. PCT ELECSYS® using
an automated Roche Elecsys and Cobase immunoassay
analyser [20]. This new assay is more sensitive compared
with the conventional assays, and the sensitivity of this
assay is 0.02 ng/ml. CRP level was determined using a fully
automated IMMAGE Immunochemistry System (Beckman
Coulter, USA), which was derived from the highly sensitive
near infrared particle immunoassay method. The lower
limit of detection is 3.45 mg/L.
Statistical analysis
Normally distributed variables are presented as the
mean +/− standard deviation (SD), and nonparametric
continuous variables are expressed as the median
and inter-quartile ranges (IQR). PCT levels among
sepsis groups or GCS groups were carried out using
Kruskal-Wallis tests (data not normally distributed),
if statistical significance of differences was detected,
then the Mann–Whitney U-test (nonparametric analysis)
was used for further comparisons between the two sepsis
groups or GCS groups. We used the Pearson chi-square
test (χ2 test) or Fisher’s exact test to compare proportions.
Multivariate logistic regression was used to assess the
performance of the variables in the prediction of sepsis.
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confounding variables (age (p = 0.789), sex (p = 0.779), ISS
(p < 0.05)) that required adjustment to minimise their
influence on the results. Receiver operating characteristic
curves (ROC) and the area under the curve (AUC) were
employed to assess the predictive performance of the
models. A two-tailed p value < 0.05 was considered to be
statistically significant. Statistical evaluation of data was
analysed using the SPSS version 17.0 software.
Results
Demographics and clinical characteristics of patients
One hundred five isolated traumatic brain injury patients
without underlying illness or long-term medication were
admitted within 24 hours after accident. Among these
patients, 90 (85.7%) were traumatised by motor vehicle,
whereas 15 casualties were suffered from trauma following
a fall from a greater height. The mean age of the patients
was 56 years and ranged from 18 to 80 years with 79
males and 26 females. The demographics and clinical
characteristics of patients are presented in Table 1.
Generation of PCT and CRP after trauma
The median levels of serum PCT and CRP in the overall
patient cohort were 0.2 ng/ml and 23.1 mg/L, respectively.
After comparisons were carried out among the different
groups that were divided according to their GCS scores,
an incremental increase in the median level of PCT that
was consistent with increasing severity of brain injury was
observed. The median level of PCT in patients with mild
brain injury was significantly lower than that in patients
with moderate and severe brain injury. The dynamic
changes of PCT and CRP levels after neurotrauma are
depicted in Figure 1.
Development of sepsis
The incidence of SIRS or sepsis occurred in 79% patients
with traumatic brain injury. Among 105 patients, 71
(67.6%) were clinically diagnosed as septic including 15
patients (14.3%) who suffered from severe sepsis or
septic shock. Positive blood culture was detected in 43Table 1 Demographic data of series of patients by GCS subgr
Parameters GCS13-15
Number (n) 33
Age (mean ± SD) 55 ± 14
Gender (male/female) 21/12
ICU stay(d) 12.4 ± 5.5
Initial ISS 4 ± 3
Initial C-reactive protein (0–24 hours) (median, quartiles) (mg/l) 10.23(3.5,1
Initial procalcitonin (0–24 hours)(median, quartiles) (ng/ml) 0.08(0.05,0
Mortality (%) 1.0pneumonia patients, 10 peritonitis patients, 9 urinary
tract infection patients, 7 wound infection patients and
8 patients with infection of other parts of body. Sepsis,
severe sepsis or septic shock was frequently and directly
diagnosed during the observation period in patients with
initially high levels of serum PCT. On the contrary, the
initial level of CRP was not associated with these
categories of infection as shown in Figure 2 and Table 2.
For example, the patients PCT level with 0.05 ng/ml that
ranged from <0.03 to 0.098 ng/ml initial median (quartiles)
did not develop SIRS or sepsis during the entire course of
observation. Conversely, the patients with 0.105 ng/ml that
ranged from 0.085 to 0.328 ng/ml initial median PCT level
developed SIRS (p = 0.002), and those with 0.27 ng/ml that
ranged from 0.12 to 0.61 ng/ml initial median PCT level
developed sepsis (p = 0.001). The patients with 0.57 ng/ml
that ranged from 0.23 to 1.45 ng/ml initial median PCT
level developed septic shock (p < 0.001). There was a
significant difference in the initial level of PCT between
SIRS and sepsis (p = 0.046). PCT concentration remained
elevated in patients with sepsis, severe sepsis or septic
shock, but it rapidly fell to a near-normal value in the
patients who did not develop sepsis (Figure 3). There was a
significant difference in the median level of PCT between
the measurements at admission and 7 days after admission
(0.32 vs 0.2 ng/ml, p < 0.002). Univariate logistic regression
analysis indicated that the initial white blood cell count
(WBC), CRP and PCT were the high risk factors for
sepsis/severe sepsis or septic shock, and after adjusting for
these parameters, multivariate logistic regression analysis
indicated that the odds ratio for the development of
sepsis/severe sepsis or septic shock increased if PCT
was >0.215 ng/ml, but other markers had no statistical
significance (Table 3).
Serum PCT and prognosis
Of the 105 patients, 16 died of severe head trauma
with a GCS score of 3–8 within 28 days after trauma,
which accounted for 15.24% mortality. The initial
PCT and CRP levels after trauma were significantly
higher in nonsurvivors than those in survivors (p < 0.05 byoup
Group GCS9-12Group GCS3-8Group Totality p value
38 34 105 -
56 ± 14 55 ± 14 55 ± 13 1.0
31/7 27/7 79/26 0.172
15.2 ± 9.6 16 ± 7.1 14.6 ± 7.7 0.125
13 ± 5 17 ± 5 12 ± 7 0.001
5.9) 23.75(13.3,42.5) 44.85(22.4,78.1) 23.1(10.3,46.1) 0.244
.13) 0.25(0.11,0.55) 0.31 (0.17,0.79) 0.2(0.08,0.5) 0.110
2.9 11.3 15.2 0.000
Figure 1 Serum levels of procalcitonin (PCT) and C-reactive
protein (CRP) in patients with neurotrauma. Time course of
induction (median, quartiles).
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ior compared to CRP in the prediction of mortality with a
greater area under the ROC curve (0.76 vs 0.733).Discussion
TBI patients present a particular challenge in the diagnosis
of sepsis complications as the trauma per se predisposes
patients to provoking a systemic inflammatory response
that often masks the initial clinical symptoms of sepsis.
Therefore, patients with TBI are considered to be at a
high risk for sepsis complications, which complicate
the ability to distinguish sepsis from SIRS in a clinical
setting by using ordinary clinical signs and symptoms such
as WBC, high fever and mal-perspiration. Alternatively,Figure 2 The initial serum concentration of procalcitonin (PCT)
and C-reactive protein (CRP) after neurotrauma and the
development of septic complication during a 28-day follow-up.
SIRS: systemic inflammatory response syndrome, *p < 0.05,
Mann–Whitney U test.PCT is considered as an acute-phase biomarker of the
systemic inflammatory response [27]. We carried out this
study to determine whether PCT and CRP can be diagnos-
tic markers of sepsis or prognostic indicators of mortality
of neurotrauma patients.
In the present study, PCT level increased in the first
24 hours after trauma in patients with GCS < 12.
However, the median PCT level in patients with GCS
9–12 was lower than that of the patients with GCS < 8.
Various levels of PCT and CRP were detected in patients
with TBI. Both biomarkers showed that the variation
of CRP levels at different intervals after trauma was a
uniform response without significant association with
trauma severity. The development of various stages of
sepsis was also observed. Furthermore, the concentration
of CRP remained elevated for several days after trauma.
The variation of PCT levels was moderately consistent
with the severity of the trauma that was previously
reported by several authors [5,28,29]. Of particular note,
the initial median level of PCT was closely associated with
the severity of TBI. The mechanism of this phenomenon
could be explained by the observation that SIRS is a
more common occurrence that is promptly activated
in neurotrauma patients or that the PCT level is
assayed by a sophisticated instrument, therefore, this
phenomenon diminished the value of PCT being used
as a specific marker of sepsis in these patients.
As noted, the median PCT, but not CRP, level was
determined to be significantly higher in patients with
sepsis, severe sepsis or septic shock compared to the
levels in patients with SIRS after the evaluation of
patients according to criteria established by the
ACCM/SCCM. CRP is another acute inflammatory
protein and it often takes a long time to activate a
reaction whereby its levels are elevated in response
to inflammation. Studies have shown that the kinetics
of CRP in multiple-trauma is slower and sustains
longer than PCT [30]. These findings could be due
mainly to the low sensitivity of CRP that is responsive to
trauma at an early stage. According to the multivariate
logistic regression analysis, after adjustment for age
and gender, the PCT value was an independent risk
factor of sepsis. Patients with high initial PCT levels
were subjected to a 290-fold risk of sepsis compared
to those with a low initial PCT level.
There are several studies that have reported using
PCT to guide antibiotic therapy in different settings
[31-33]. Experts have reached a consensus and developed
guidelines for the clinical interpretation of elevated
PCT and the risk stratification according to different
elevated PCT levels. In particular, the negative predictive
value (PCT < 0.1 ng/ml) to exclude a risk of sepsis is
used. In the present study, we conventionally adminis-
tered a single shot antibiotic to neurotrauma patients
Table 2 The original data of PCT and CRP in patients of sepsis subgroup
Group PCT (ng/ml)(d1) CRP (mg/L)(d1) PCT (ng/ml)(d2)
Median IQR Median IQR Median IQR
No SIRS 0.093 (0.050,0.093) 4.86 (3.22,10.30) 0.120 (0.080,0.300)
SIRS 0.105 (0.085,0.328) 21.90 (14.48,42.22) 0.295 (0.148,0.575)
Sepsis 0.270 (0.120,0.610) 27.85 (15.12,55.50) 0.555 (0.233,0.857)
Severe sepsis 0.570 (0.230,1.450) 34.30 (22.40,154.0) 1.300 (0.360,2.600)
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the odds ratio for the development of sepsis was increased
as PCT > 0.215 ng/ml, and according to the daily meas-
urement of the PCT value, if PCT remains lower than
0.1 ng/ml, further antibiotic treatment was not required
due to the low risk for sepsis. This finding was consistent
with Marc and colleagues [33]. We also determined that
PCT concentration rapidly decreased to a near-normal
value in patients who did not develop sepsis, thus, during
the further course of treatment, if the PCT level
remained <0.1 ng/ml and the combined clinical symptoms
did not provided any evidence for sepsis, no antibiotics
were required. Thus, the daily use of the negative predictive
value of PCT would be clinically helpful.
Our study has several important implications for clini-
cians. Although the present study population is too
small to infer the importance of serum PCT in neuro-
trauma patients, it definitively indicates that serum PCT
could be involved in the entire course of infections to
facilitate the management of sepsis in critical care.
With the newest assay method, serum PCT is detected
with a high accuracy that other currently available
tests cannot provide. The accuracy of the serum PCT
reference range is not perfect, but it could guide physiciansFigure 3 Course of procalcitonin (PCT) in patients who
developed various stages of severe sepsis, sepsis, systemic
inflammatory response syndrome (SIRS), or NoSIRS
(median, quartiles).in developing a clinical strategy and incrementally
managing neurotrauma patients with sepsis. Additionally,
the daily measurement of PCT aids physicians in guiding
antibiotic therapy in neurotrauma patients. The test can
be performed within 30 minutes and provides valuable
information long before culture results are available.
There are some limitations to the present study. First,
the sample size of the study was relatively small, and
consequently, the power to demonstrate the interaction
among serum PCT and prognosis was limited. Second,
most patients were young males, which did not represent
the entire demographics of neurotrauma patients. Third,
the present study did not analyse the kinetics of PCT
level and its association with other inflammatory cytokines
levels in these patients. Finally, the pathophysiology of
neurotrauma was complex and was influenced by
patient-specific factors (age, sex) and injury-specific
factors (mechanism, severity). Thus, one single biomarker
will not be able to accurately predict the clinical course of
neurotrauma patients.Conclusions
These data substantiate the hypothesis that increased
levels of PCT during the period of hospitalisation could
be an important indicator for the early recognition of
bacterial infection and sepsis as well as provide early
information about the presence of complications after
TBI. These data also indicate that the daily measurement
of PCT would be clinically useful. The authenticity and
soundness of the findings obtained from our study need
to be evaluated in a future study.Table 3 Multivariate logistic regression analysis of the
risk factors of sepsis
B S.E. Wald p odds ratio
Initial WBC 0.062 0.077 0.661 0.416 1.064
Sex 0.580 0.836 0.481 0.488 1.787
Age 0.010 0.027 0.148 0.700 1.010
initial ISS 0.352 0.084 17.694 0.000 1.422
Initial CRP 0.016 0.013 1.600 0.206 0.984
Initial PCT 5.672 2.399 5.589 0.018 290.681
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